About 세레스에프앤디의 연구를 소개합니다.

    2020
    06.302020 Chungbuk Regional SMEs (Small and Medium-sized Enterprises) Award (Promising Entrepreneurship Division) in the First Half of the Year
    03.01Institute of Industrial-academic Cooperation (Sogang University)
    2019
    12.30Extend Production plant for Tacrolimus (Immunosuppressant) construction permission & Plant registration change completed
    11.01Jecheon PlantSuitable Process Safety Management (PSM) (Ministry of Labor)
    10.23Extend Production plant for Tacrolimus (Immunosuppressant) completion
    10.16MOU contract with Stride Pharma Science Ltd, India for Tacrolimus supplying U.S. Market
    10.01Jecheon Plant Suitable for Toxic chemicalshandling facility by Environment Offsite consequence analysis (Ministry of Environment)
    09.26Relocation of Headquarters (100, BioValley 2-ro, Jecheon-si, Chungcheongbuk-do)
    06.30Process Safety Management (PSM), Environment Offsite consequence analysis (OCA)
    02.28Approved as a venture company
    2018
    11.26Institute of Industrial-academic Cooperation (Hankuk University of Foreign Studies, Bioscience and Biotechnology)
    10.26Contract world copyright of Recombinant Human Hyaluronidase developed by Alteogen
    09.13Succession for item registration of medicinal products Vancomycin, Teicoplanin, Tacrolimus (Ministry of Food and Drug Safety)
    08.28Succession for authorization of medicine manufacturing company and KGMP certified company (Ministry of Food and Drug Safety, Daejeon)
    08.17Plant registration (Jecheon city hall)
    08.14Acquired Genotech, Jecheon plant
    07.19Excellence inTechnology Evaluation Company (NICE Information Service Co., Ltd.)
    07.16Certified Research Institute (Korean Industrial Technology Association, No.2018113631)
    06.15Corporation establishment, Inauguration of the CEO Jae Min Son